Theratechnologies Secures Canadian Rights for Ionis RNA Medicines

Theratechnologies ( (TSE:TH) ) has provided an update.

Theratechnologies Inc. announced a licensing agreement with Ionis Pharmaceuticals to commercialize two investigational RNA-targeted medicines in Canada: olezarsen for familial chylomicronemia syndrome and severe hypertriglyceridemia, and donidalorsen for hereditary angioedema. This collaboration bolsters Theratechnologies’ commitment to growth and innovation in North America, enhancing its market presence and offering new treatment options for Canadian patients.

More about Theratechnologies

Theratechnologies Inc. operates in the pharmaceutical industry and is primarily focused on providing innovative treatments for unmet medical needs across Canada, expanding from its foundational HIV portfolio in the U.S.

YTD Price Performance: -10.49%

Average Trading Volume: 50,296

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $66.62M

For a thorough assessment of TH stock, go to TipRanks’ Stock Analysis page.